Checkpoint inhibition immunotherapy has also been applied to the treatment of BC, but only 25% advanced/metastatic bladder cancers respond to anti-programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) immune checkpoint blockade (ICB) (12). This evidence concerns the gene CD274 and urinary bladder cancer.